Cross Shawn 4

What Happened

• Shawn Cross, Chief Financial Officer of Pacira BioSciences (PCRX), exercised 12,941 stock options (exercise price $16.45) on April 23, 2026, paying $212,879 to acquire the shares, and sold the same 12,941 shares in an open-market transaction that day for total proceeds of $325,596 (weighted-average sale price $25.16). An additional Form 4 line shows the derivative conversion (exercise) recorded at $0, which is a technical reporting entry for the option conversion.
• This is an exercise-and-sell (same-day) transaction: the options were converted into shares and those shares were sold the same day. Net pre-tax proceeds from the sale minus exercise cost were approximately $112,717.

Key Details

• Transaction date: April 23, 2026; Form 4 filed April 24, 2026 (timely).
• Exercise price paid: $16.45 per share; total cash paid $212,879.
• Sale: 12,941 shares sold at a weighted-average price of $25.16 (range $25.00–$25.41); total proceeds $325,596. The filer can provide a breakdown of shares sold at each price on request (see footnote).
• Shares owned after transaction: not provided in the materials supplied here (see the full Form 4 for beneficial ownership after the transaction).
• Footnotes of note:
  • Transaction executed under a pre-established Rule 10b5-1 trading plan adopted June 9, 2025 (F1).
  • Sale price is a weighted average; individual trade prices ranged $25.00–$25.41 (F2).
  • The option’s vesting schedule: 25% on the first anniversary of grant, remainder in equal quarterly installments over the next three years (F3).
• Filing status: appears timely (transaction 4/23/2026; Form 4 filed 4/24/2026).

Context

• Same-day exercise and sale is a common way for insiders to realize gains from vested options while recognizing the exercise cost; the filing shows the mechanics (exercise then sale) and that the trades were placed via a 10b5-1 plan. This report is factual disclosure of the transactions and does not, by itself, indicate the insider’s future view of the company.